3417.T

• Corporate Mission & Structure

  • As a healthcare wholesale infrastructure provider, the company anchors its operations on the core principle of contributing to public healthcare through all products and services, targeting medium- to long-term growth while upholding its foundational corporate philosophy. It is planning corporate restructuring to strengthen holding company functions, with core wholesale operations under the central intermediate distribution segment, supported by dedicated manufacturing planning and retail subsidiaries, as well as overseas operations for the Chinese market and other ASEAN regions.
  • The company operates a unique business model that expands beyond basic product delivery: it co-creates new healthcare categories with retailers, supports custom distribution for new entrants (such as large e-commerce platforms entering the OTC market), and offers specialized Store Philosophy Brand (SPB) private label development that integrates each retailer's core philosophy, rather than only developing low-cost generic alternatives that shrink overall market size.
  • It provides end-to-end support for retailers including category management, shelf planning, advertising, public authority liaison, and facility partnership, and supports manufacturers with test marketing, product development, production lot management, and distribution channel strategy planning, filling gaps that pure wholesale distributors do not address.

• Logistics Network Operations

  • The company maintains a nationwide distribution network centered on small and medium-sized hubs arranged spiderweb-style across Japan, specialized for small-batch, multi-SKU, high-frequency delivery of healthcare products, delivering even single units of low-price items without disproportionately high logistics costs by keeping operating expenses low through continuous efficiency improvements.
  • It is implementing mechanization and labor-saving initiatives to address labor shortage challenges, has nearly fully implemented EDI integration with retailers for automatic order processing and inventory handling, and is investing to advance EDI adoption with manufacturers. It also introduced a reservation system for logistics center loading/unloading to reduce truck driver waiting time, and adapts its distribution network through frequent (every 3 months) hub adjustments within operating cost budgets to match changes in retail logistics footprints, maintaining high operational flexibility.

• Financial & Operational Initiatives

  • The company has achieved over 20 consecutive years of revenue growth, with a temporary reported sales dip from a prior accounting standard change for revenue recognition. It increased dividends by 2 yen per share to 26 yen per share this term, following stable profit growth.
  • The company spent approximately 1 billion yen on forward investments this term, including three consecutive years of wage increases to maintain competitive pay for talent retention, in-house training for AI and data analysis capabilities, U.S. study tours for mid-tenure employees to drive organizational change, system investment for customer management and order processing, logistics efficiency improvement, and minority investments for knowledge sharing with specialized firms.

• The company announced a new medium-term management plan targeting 400 billion yen in consolidated revenue and 4 billion yen in consolidated operating profit by 2028, the company's 370th anniversary. Management describes this as a challenging but achievable target that prioritizes transforming the business model and making forward investments, with a deliberately conservative sales target to accommodate the ongoing transformation.
  • Inventory levels are planned to be reduced back to a 0.6-month sales baseline from the current elevated stock built for shortage prevention, which will improve cash flow going forward.
  • The company plans to complete the relocation of its headquarters function to the newly acquired headquarters building over a six-month period starting in autumn 2025.

For the 2025 March term, standalone sales were 347.213 billion yen, and consolidated sales reached 349.453 billion yen, achieving year-over-year revenue growth. Consolidated operating income was 2.768 billion yen, an increase year-over-year, while standalone operating income was 2.565 billion yen, a slight decrease from the prior year. By product category: OTC pharmaceuticals account for approximately 40% of total standalone sales. All categories including OTC pharmaceuticals, health foods, cosmetics, and oral care products achieved year-over-year revenue growth. The mask business, led by subsidiary Rib Laboratories, has stabilized after the post-COVID correction and remains the top-selling mask brand by volume in Japan.

• Labor shortage: Despite the company's smaller per-hub staffing model improving hiring outcomes relative to peer wholesale firms, it still faces challenges securing sufficient talent, requiring continued investment in mechanization and labor-saving initiatives.
  • Logistics cost inflation: The 2024 trucking industry regulatory changes have driven industry-wide increases in logistics and delivery costs, which the company manages through cost structure adjustments but remains an ongoing headwind.
  • Market education barriers for new femcare categories: Japan lacks open public discussion and education around women's health, which slows adoption of new femtech products, requiring long-term market building before new categories can deliver meaningful sales.
  • Low product rotation: Most healthcare products have inherently low purchase frequency, which makes demand data less reliable and complicates new product development, requiring the company to provide specialized support that adds operational complexity.

Q: Which sales category does femcare product fall into, and what is the company's strategy for growing the femcare business amid growing interest in foreign femtech products? / A: Management notes that femcare is still an emerging category for the company, and Japan's market differs significantly from the U.S. due to a lack of public education and open discussion around women's health. For example, tampon usage is far lower in Japan than in Western markets because usage is not taught in public schools, so new products like menstrual cups will require significant market education to reach mainstream consumers. The company is focusing first on building public awareness through its LAUGHBASE subsidiary, starting with internal education for employees, before rolling out broad new product offerings, prioritizing improving usage knowledge for existing products before launching large numbers of new femtech items.

Q: How did the collaboration with SS Pharmaceutical come about, and what is the company's role and future plan for collaborations with direct-to-consumer manufacturers? / A: Ohki initiated the conversation based on the belief that a hybrid model combining direct-to-consumer sales and wholesale distribution is better for the Japanese market than choosing only one channel. SS Pharmaceutical wanted to launch switch OTC and direct switch products but lacked Ohki's broad nationwide distribution reach to local pharmacies and retail outlets, while Ohki gained access to SS Pharmaceutical's strong national brand portfolio, creating a mutually beneficial partnership. Management is open to future collaborations with other direct-to-consumer manufacturers that share the company's vision. The company sees it as an industry-building initiative: supporting pharmacies to offer a full range of healthcare products will not deliver large short-term profits, but it is necessary to move the entire healthcare industry forward, and Ohki is willing to take on this role.